Bronchiectasis Treatment Stocks

Biopharmaceutical and medical technology firms in this sector focus on managing chronic airway inflammation and permanent lung dilation through advanced drug delivery systems and mechanical clearance devices.

As of Oct 23, 2026, Bronchiectasis Treatment has 3 US-listed companies worth $21.1B combined. The median member moved -3.0% over the past week; TCMD led at +5.0% and ELMD trailed at -3.8%.

Companies in Bronchiectasis Treatment

• INSM – Insmed Inc, $20.4B
• TCMD – Tactile Systems Technology Inc, $501M
• ELMD – Electromed Inc, $231M

Related groups

• Healthcare Equipment
• Commercial Stage
• Medical Devices
• Healthcare Technology
• Healthcare

All equity groups